• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

WHO’s Global Hepatitis Report sets baseline to eliminate viral hepatitis by 2030

Bioengineer by Bioengineer
April 21, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The World Hepatitis Alliance today welcomes the publication of the first-ever Global Hepatitis Report by the World Health Organization (WHO). The report comes as a follow-up to WHO's Global Strategy on Viral Hepatitis, which set a goal of eliminating viral hepatitis as a public health threat by 2030.

The report contains new baseline data on the impacts of viral hepatitis (hepatitis B and C), regionally and globally, and aims to standardise understanding of the disease; an essential starting point to measure progress towards achieving the 2030 elimination goal.

Viral hepatitis is a major public health challenge, one that requires an urgent response. The Global Hepatitis Report shows definitively, for the first-time that:

  • Viral hepatitis causes 1.34 million deaths (a number comparable to annual deaths caused by tuberculosis, HIV and malaria)
  • 325 million people live with viral hepatitis (approximately 4.4% of the world's population)
  • Only 9% of persons living with hepatitis B and 20% of persons living with hepatitis C have been tested and are aware of their status
  • Unsafe healthcare procedures and injection drug use are the leading causes of new hepatitis C infections, accounting for the majority of the 1.75 million new infections

"For the first time in the history of viral hepatitis, we have an understanding of the true impact of the disease." said Charles Gore, President of the World Hepatitis Alliance. "WHO's Global Hepatitis Report provides us with new data and a set of very specific, global and regional targets to reach by 2030 – for instance global deaths from hepatitis must be brought down from 1.34 million to lower than 469,000 people per year."

The report shows that since 2000, deaths due to viral hepatitis increased by 22%, while deaths due to other diseases such as tuberculosis, malaria, and HIV have been declining. If we are to reverse this trend, specific actions must be adopted at both a regional and national level.

One such action is the scaling up of birth dose vaccination against hepatitis B. Despite the success in rolling out childhood hepatitis B vaccination, where coverage has reached 84%, coverage with the initial birth dose vaccination is still unacceptably low at 39%. Another, highlighted in the report, is dramatically improving access to affordable treatment, which remains limited to only 1% of people living with viral hepatitis.

Raquel Peck, CEO of World Hepatitis Alliance said "Today, 325 million men, women and children are living with a cancer-causing illness despite the availability of preventative vaccines for hepatitis B and curative treatments for hepatitis C. We need to use this report to advocate for a public health approach, so that testing and treatment are rolled out at the scale necessary to ensure that every person has the opportunity to live a healthy life". She added, "We have the knowledge, what we need now is action."

On 1- 3 November, hundreds of policymakers, patients, civil society and public health experts will gather at the World Hepatitis Summit, in Sao Paulo, Brazil to discuss how to fast track the path to elimination.

The three-day event, which is a joint initiative between WHO and the World Hepatitis Alliance, will focus on key ways to implement WHO's Viral Hepatitis Strategy, with a specific focus on how to improve surveillance data, scale up testing and treatment at a national level, and support service delivery amongst vulnerable populations. The event will also encourage innovation in research and have a dedicated focus on sustainable financing for elimination, all of which are needed to eliminate viral hepatitis by 2030.

###

The full WHO Global Hepatitis Report is available here.

Media Contact

Tara Farrell
[email protected]
44-776-162-5256
@Hep_alliance

Home

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Circ_0000847 Drives Colorectal Cancer via IGF2BP2 Binding

August 22, 2025
Sensitive Surfaces and Keen Senses: Innovative Robotics Detect Threats Before Impact

Sensitive Surfaces and Keen Senses: Innovative Robotics Detect Threats Before Impact

August 22, 2025

ATOX1 Drives Hepatocellular Carcinoma Progression by Activating the c-Myb/PI3K/AKT Signaling Pathway

August 22, 2025

Unraveling Fat Maps: Microfluidics and Mass Spectrometry Illuminate Lipid Landscapes in Tiny Worms

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Circ_0000847 Drives Colorectal Cancer via IGF2BP2 Binding

Sensitive Surfaces and Keen Senses: Innovative Robotics Detect Threats Before Impact

ATOX1 Drives Hepatocellular Carcinoma Progression by Activating the c-Myb/PI3K/AKT Signaling Pathway

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.